LONDON: Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, is delighted to announce that Professor Lindy Durrant, Scancell’s Chief Scientific Officer, is to receive the Swedish Society of Oncology’s Waldenström award.
[the_ad id=”32940″]Professor Durrant will be presented with the award at the Swedish Society of Oncology Annual Meeting on Thursday 21 March 2019 at 13:30 CET in Stockholm, Sweden, and will give an honorary lecture to fellow society members. The theme of the lecture will be on novel approaches to cancer vaccinations.
The Jan Waldenström award is presented for a successful career in cancer research. Waldenström macroglobulinemia is a type of non-Hodgkin lymphoma and is named after Jan Gösta Waldenström (17 April 1906-1 December 1996), the Swedish doctor of internal medicine, who first described the disease.
Professor Lindy Durrant, co-founder and Chief Scientific Officer of Scancell, is an internationally recognised immunologist in the field of tumour therapy. She has worked for over 20 years in translational research, developing products for clinical trials including monoclonal antibodies and cancer vaccines.
Lindy and her team have developed a platform called ImmunoBody®, which uses DNA encoding human antibodies engineered to express tumour antigens, to stimulate potent killer T cells for the treatment of melanoma and lung cancer. Her team is also the first group to show that immune responses to stress induced modifications, the Moditope® platform, induces strong anti-tumour responses. Lindy also has a personal chair in cancer immunotherapy at the University of Nottingham and has published over 200 original papers and patents.
Professor Lindy Durrant, Chief Scientific Officer of Scancell, said: “I am honoured to have been awarded the prestigious Waldenström award which recognises the research my group has undertaken and its potential application to the treatment of cancer. I am proud to be leading the research at Scancell, developing products that stimulate the immune system to treat or prevent cancer recurrence and for our work to be recognised by the Swedish Society of Oncology.”